Occupational Safety and Health Administration

22 Nov.,2022


Progesterone Powder

NOAA: CAMEO Chemicals - Progesterone

NIOSH: Pocket Guide to Chemical Hazards - Progesterone

Literature References


  • National Institute for Occupational Safety and Health: NIOSH Alert: Preventing Occupational Exposure to Antineoplastic and Other Hazardous Drugs in Health Care Settings. NIOSH Publication No. 2004-165.
  • Andréen, L., Sundstrom-Poromaa, I., Bixo, M., Andersson, A., Nyberg, S. and Bäckström, T.: Relationship between allopregnanolone and negative mood in postmenopausal women taking sequential hormone replacement therapy with vaginal progesterone. Psychoneuroendocrinology 30(2): 212-224, 2005.
  • Bélanger, A., et al.: Changes in serum concentrations of conjugated and unconjugated steroids in 40- to 80-year-old men. J. Clin. Endocrinol. Metab. 79(4): 1086-1090, 1994.
  • Golub, M.S., Kaufman, F.L., Campbell, M.A. Li, L.-H., et al.: Evidence on the developmental and reproductive toxicity of progesterone (draft). Reproductive and Cancer Hazard Assessment Section, Office of Environmental Health Hazard Assessment, California Environmental Protection Agency, (August) 2004, 71 pp.
  • No authors listed: Progesterone (CAS No. 57-83-0). Report on Carcinogens (latest edition); U.S. Department of Health and Human Services, Public Health Service, National Toxicology Program, 2005.
  • Soderpalm, A.H., Lindsey, S., Purdy, R.H., Hauger, R. and Wit de H.: Administration of progesterone produces mild sedative-like effects in men and women. Psychoneuroendocrinology 29(3): 339-354, 2004.
  • Trévoux, R., De Brux, J., Castaner, M., Nahoul, K., Soule, J.-P. and Scholler, R.: Endometrium and plasma hormone profile in the peri-menopause and post-menopause. Maturitas 8(4): 309-326, 1986.